Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinicopathologic implication of A20/TNFAIP3 deletion in diffuse large B-cell lymphoma: an analysis according to immunohistochemical subgroups and rituximab treatment.

Leukemia & lymphoma - 1 Sept 2013

Paik Jin Ho, Go Heounjeong, Nam Soo Jeong, Kim Tae Min, Heo Dae Seog, Kim Chul-Woo, Jeon Yoon Kyung

Abstract excerpt

We analyzed the clinicopathologic implication of A20/tumor necrosis factor α-induced protein 3 deletion in diffuse large B-cell lymphoma (DLBCL) using fluorescence in situ hybridization, according to germinal center B-cell (GCB) versus non-GCB/activated B-cell (ABC) phenotypes and rituximab treatment. Excluding primary central nervous system (CNS) and Epstein-Barr virus (EBV)-positive lymphomas, 134 DLBCLs were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Murine-Derived
Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to In Situ Hybridization, Fluorescence

Share to Intracellular Signaling Peptides and Proteins

Share to Lymphoma, Large B-Cell, Diffuse

Share to Neoplasm Staging

Share to Rituximab

Share to Tumor Necrosis Factor alpha-Induced Protein 3

Source

Identifiers

PMID: 23327292
DOI: 10.3109/10428194.2012.762511

Genes

TNFAIP3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinicopathologic implication of A20/TNFAIP3 deletion in diffuse large B-cell lymphoma: an analysis according to immunohistochemical subgroups and rituximab treatment.PMID 23327292Read ↗

Molecular pathogenesis and treatment strategy in diffuse large B-cell lymphoma.Semantic proximity Read ↗

A20 (TNFAIP3) Alterations in Primary Intestinal Diffuse Large B-cell Lymphoma.Semantic proximity Read ↗

Diffuse large B cell lymphoma: using pathologic and molecular biomarkers to define subgroups for novel therapySemantic proximity Read ↗

Genetic lesions in diffuse large B-cell lymphomas.Semantic proximity Read ↗

Novel therapeutic targets in diffuse large B-cell lymphomaSemantic proximity Read ↗

Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B‐cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximabSemantic proximity Read ↗

Comprehensive Genomic Profiling of EBV-Positive Diffuse Large B-cell Lymphoma and the Expression and Clinicopathological Correlations of Some Related GenesSemantic proximity Read ↗

A novel A20 (TNFAIP3) antibody (Ber-A20) can be used to detect unmutated A20 by immunohistology.Semantic proximity Read ↗

Anaplastic Variant of Diffuse Large B-cell Lymphoma Displays Intricate Genetic Alterations and Distinct Biological Features.Semantic proximity Read ↗

Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma.Semantic proximity Read ↗

<i>MYC</i> translocation and an increased copy number predict poor prognosis in adult diffuse large B‐cell lymphoma (DLBCL), especially in germinal centre‐like B cell (GCB) typeSemantic proximity Read ↗

Colorectal diffuse large B-cell lymphoma: molecular subclassification and prognostic significance of immunoglobulin gene translocation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.